Title: The effects of metformin on cardiovascular risk factors
Abstract: Diabetes/Metabolism ReviewsVolume 11, Issue S1 p. S43-S50 Article The effects of metformin on cardiovascular risk factors Peter J. Grant, Corresponding Author Peter J. Grant Diabetes and Thrombosis Research Group, University of Leeds, UKDiabetes and Thrombosis Research Group, Division of Medicine, G Floor, Martin Wing, The General Infirmary, Leeds LS1 3EX, U.K.Search for more papers by this author Peter J. Grant, Corresponding Author Peter J. Grant Diabetes and Thrombosis Research Group, University of Leeds, UKDiabetes and Thrombosis Research Group, Division of Medicine, G Floor, Martin Wing, The General Infirmary, Leeds LS1 3EX, U.K.Search for more papers by this author First published: September 1995 https://doi.org/10.1002/dmr.5610110507Citations: 12AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Reaven GM: Role of insulin resistance in human disease. Diabetes 37: 1595–1607, 1988. 2 Vague J: The degree of masculine differentiation of obesities, a factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr 4: 20–34, 1956. 3 Pyorala K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2: 131–141, 1979. 4 Ducimetiere P and, Eschwege E, Papoz L, Richard JL, Claude JR, and Rosselin G: Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 19: 205–210, 1980. 5 Welborn TA, and Wearne K: Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 2: 154–160, 1979. 6 Modan M and, Halkin H, Lusky A, Segal P, Fuchs Z, and Cherit A: Hyperinsulinaemia is characterised by jointly disturbed plasma, VLDL, LDL, and HDL levels: a population-based study. Arteriosclerosis 8: 227–236, 1988. 7 Haffner SM and, Stern MP, Hazuda HP, Mitchell BD, and Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes. JAMA 263: 2893–2898, 1990. 8 Landin K and, Tengvory L, and Smith U: Elevated fibrinogen and plasminogen activator (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 227: 273–278, 1990. 9 Juhan-Vague I, Alessi MC, and Vague P: Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 34: 457–462, 1991. 10 Bailey CJ: Biguanides and NIDDM. Diabetes Care 15: 755–772, 1992. 11 Campbell IW and, Menzies DG, Chalmers J, McBain AM, and Brown IRF: One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab 20: 146–149, 1994. 12 Nagi D, and Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 16: 621–629, 1993. 13 Vague P and, Juhan-Vague I, Alessi MC, Badier C, and Valadier J: Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 57: 326–328, 1987. 14 Landin K and, Tengborn L, and Smith U: Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 229: 181–187, 1991. 15 Velazquez EM and, Mendoza S, Hamer T, Sosa F, and Glueck CJ: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinaemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43: 647–654, 1994. 16 Grant PJ and, Stickland MH, Booth NA, and Prentice CRM: Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabetic Med 8: 361–365, 1991. 17 Montaguti U and, Celin D, Ceredi C, and Descovich GC: Efficacy of the long-term administration of metformin and hyperlipidaemic patients. Res Clin Forums 1: 95–103, 1979. 18 Haupt E and, Knick B, Koschinsky T, Liebermeister H, Schneider J, and Hirche H: Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab 17: 224–231, 1991. 19 Campbell IW and, Duncan C, Patton NW, Broadhead T, Tucker GT, and Woods HF: The effect of metformin on glycaemic control, intermediary metabolism and blood pressure in non-insulin-dependent diabetes mellitus. Diabetic Med 4: 337–341, 1987. 20 Teupe B, and Bergis K: Prospective randomised two years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete Metab 17: 213–217, 1991. 21 Landin K and, Tengborn L, and Smith U: Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinaemic euglycemic clamp in man. Thromb Haemost 71: 783–787, 1994. 22 Giugliano D and, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, and D'Onfrio F: Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 16: 1387–1390, 1993. 23 Chan JCN and, Cockram CS, Tomlinson B, Walden RJ, and Critchley JAJH: Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 16: 1035–1038, 1993. 24 Dornan TL and, Heller SR, Peck GM, and Tattersall RB: Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 14: 342–344, 1991. 25 Chakrabarti R and, Hocking D, and Fearnley GR: Fibrinolytic effect of metformin in coronary artery disease. Lancet ii: 256–259, 1965. 26 Hocking ED and, Chakrabarti R, Evans J, and Fearnley GR: Effects of biguanides and atromid on fibrinolysis. J Atheroscl Res 7: 121–130, 1967. 27 Montanari G and, Bondioli A, Rizzato G, Puttini M, Tremoli E, Mussoni L, Mannucci L, Pazzucconi F, and Sirtori CR: Treatment with low dose metformin in patients with peripheral vascular disease. Pharm Res 25: 63–73, 1992. 28 Sirtori CR and, Tremoli E, Sirtori M, Conti F, and Paoletti R: Treatment of hypertriglyceridaemia with metformin. Atherosclerosis 26: 853–862, 1977. 29 Sirtori CR and, Franceshini G, Gianfranschi G, Sirtori M, Montanari G, Bosisio E, Mantero E, and Bondioli A: Metformin improves peripheral vascular flow in non-hyperlipidemic patients with arterial disease. J Cardiovasc Pharmacol 6: 914–923, 1984. 30 Landin K and, Tengborn L, and Smith U: Metformin and metoprolol CR treatment in non-obese men. J Intern Med 235: 335–341, 1994. 31 Bachman F: Fibrinolysis. In Thromobis and Haemostasis, M Verstraete, J Vermylen, R Lijnen, and J Arnout, Eds. Leuven University Press, Belgium, 1987, pp. 227–265. 32 Kruithof EKO: Plasminogen activator inhibitors: a review. Enzyme 40: 113–121, 1988. 33 Hamsten A and, Wiman B, deFaire U, Blomback M: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313: 1557–1563, 1985. 34 Hamsten A, deFaire U and, Waldius G, Dahlen G, Szamosi A, Landou C, Blomback M, and Wiman B: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet ii: 3–9, 1987. 35 Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801–809, 1993. 36 Prins MH and, Hirsh J: A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med 151: 1721–1731, 1991. 37 Walmsley D and, Hampton KK, Grant PJ: Contrasting fibrinolytic responses in type 1 (insulin dependent) and type 2 (non insulin dependent) diabetes. Diabetic Med 8: 954–959, 1991. 38 Auwerx J and, Bouillon R, Colen D, and Geboers J: Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8: 68–72, 1988. 39 Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, and Vague P: Increased plasminogen activator inhibitor in non insulin dependent diabetic patients: relationship to plasma insulin. Thromb Haemost 61: 370–373, 1989. 40 Mykkanen L and, Ronnemaa T, Marniemi J, Haffner SM, Bergman R, and Laakso M: Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterio Thromb 14: 1264–1271, 1994. 41 Juhan-Vague I, Allessi MC, Joly P, Thirion X, Vague P, Declerck PJ, Serradimigni A, and Collen D: Plasma plasminogen activator inhibitor-1 in angina pectoris: influence of plasma insulin and acute phase response. Arteriosclerosis 9: 362–367, 1989. 42 Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, and Atlan C: Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diabete Metab 13: 331–336, 1987. 43 Vague P and, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, and Collen D: Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 35: 250–253, 1986. 44 Gough SCL and, Rice PJS, McCormack L, Chapman C, and Grant PJ: The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. Diabetic Med 10: 638–642, 1993. 45 Grant PJ and, Ruegg M, and Medcalf P: Basal expression and insulin-mediated induction of mRNA in Hep G2 cells. Fibrinolysis 5: 81–86, 1991. 46 Kooistra T and, Bosma PJ, Tons HAM, van der Berg AP, Meyer P, and Princen HMG: Plasminogen activator inhibitor 1: biosynthesis of mRNA levels are increased by insulin in cultured human hepatocytes. Thromb Haemost 62: 723–728, 1989. 47 Alessi MC and, Juhan-Vague I, Kooistra T, Declerck PJ, and Collen D: Insulin stimulates the synthesis of plasminogen activator inhibitor by the human hepatocellular cell line Hep G2. Thromb Haemost 60: 491–494, 1988. 48 Grant PJ and, Kruithof EKO, Felley CP, Felber JP, and Bachmann F: Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor 1 concentrations in man. Clin Sci 79: 513–516, 1990. 49 Potter van Loon B, de Bart ACW, Radder JK, Frolick M, Kluft C, and Meinders AE: Acute exogenous hyperinsulinaemia does not result in elevation of plasma plasminogen activator inhibitor (PAI-1) in humans. Fibrinolysis 1990; 4 (Suppl 2): 93–94, 1990. 50 Landin K and, Tengborn L, Chmielewska J, von Schneck H, and Smith U: The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost 65: 130–133, 1991. 51 McCormack L and, Stickland MH, and Grant PJ: Plasminogen activator inhibitor-1 antigen concentrations during insulin and oral glucose tolerance tests in obese man. Fibrinolysis 7: 225–228, 1993. 52 Potter van Loon BJ, Lkuft C, Radder JK, Blankenstein MA, and Meinders AE: The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42: 945–949, 1993. 53 Fearnley GR and, Chakrabarti R, and Evans JF: Effect of ethyloestrenol combined with phen-formin or with metformin on platelet stickiness and serum-cholesterol in patients with occlusive vascular disease. Lancet ii: 1004–1007, 1968. 54 Heikinheimo R: Metformin and fibrinolysis. Scand J Haematol 6: 288–290, 1969. 55 Sadananda B and, Yesikar SS, Misra NP, and Misra SM: Effect of metformin on fibrinolytic activity in diabetes mellitus. J Diabetic Assoc of India xiv: 33–38, 1974. 56 Cho YW and, Yang DH, Oh DY, Baick SH, Kim SK, Kim SJ, and Hong SY: Plasma t-PA and PAI-1 antigen concentrations in non-insulin dependent diabetic patients: Effects of treatment modality on fibrinolysis. Korean J. Int. Med 7: 81–86, 1992. Citing Literature Volume11, IssueS1Supplement: Diabetes/Metabolism ReviewsSeptember 1995Pages S43-S50 ReferencesRelatedInformation
Publication Year: 1995
Publication Date: 1995-09-01
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 19
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot